HK Stock Market Move | SINO BIOPHARM(01177) rose more than 3% recently, and the approval for the launch of ibuprofen sodium gel patches and tadalafil patches has been granted.

SINO BIOPHARM (01177) rose more than 3%, as of the market close, it was up 3.62% at HKD 3.15, with a turnover of HKD 174 million. On the news front, on February 7th, SINO BIOPHARM announced that the group's developed "Loratadine Sodium Gel Patch" (trademark name: Deshuping) has obtained approval for listing from the China National Medical Products Administration. It is used for anti-inflammatory and analgesic effects for osteoarthritis, muscle pain, and swelling and pain caused by trauma. Deshuping is the only domestically produced Loratadine Sodium Gel Patch on the market that has been approved through consistency evaluation and clinical trials. Loratadine Sodium is a phenylpropanolic non-steroidal anti-inflammatory drug that works by inhibiting cyclooxygenase, blocking prostaglandin synthesis, and thus has anti-inflammatory, antipyretic, and analgesic effects. On the same day, SINO BIOPHARM announced that the group's developed "Tusatro Patch" (trademark name: Derituo) has obtained approval for listing from the China National Medical Products Administration. It is used to relieve respiratory difficulties caused by airway obstructive diseases such as bronchial asthma, acute bronchitis, chronic bronchitis, and emphysema. This is the first domestically produced external patch for airway obstructive diseases to be approved for listing. The Tusatro Patch acts on the beta-2 receptors of bronchial smooth muscle, dilates the bronchi, relaxes bronchial muscles, improves lung function, promotes ciliary movement, and has an antitussive effect.